Your browser doesn't support javascript.
loading
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
Peters, S; Reck, M; Smit, E F; Mok, T; Hellmann, M D.
Affiliation
  • Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.
  • Reck M; Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), Grosshansdorf, Germany.
  • Smit EF; Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mok T; State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China.
  • Hellmann MD; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York; Parker Institute for Cancer Immunotherapy, New York, USA.
Ann Oncol ; 30(6): 884-896, 2019 06 01.
Article in En | MEDLINE | ID: mdl-30912805
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: United kingdom